LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Laboratory of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, B-3001 Leuven, Belgium.
FEMS Microbiol Rev. 2019 Nov 1;43(6):622-641. doi: 10.1093/femsre/fuz021.
Staphylococcus aureus (S. aureus) is considered by the World Health Organization as a high priority pathogen for which new therapies are needed. This is particularly important for biofilm implant-associated infections once the only available treatment option implies a surgical procedure combined with antibiotic therapy. Consequently, these infections represent an economic burden for Healthcare Systems. A new strategy has emerged to tackle this problem: for small bugs, small particles. Here, we describe how nanotechnology-based systems have been studied to treat S. aureus biofilms. Their features, drawbacks and potentialities to impact the treatment of these infections are highlighted. Furthermore, we also outline biofilm models and assays required for preclinical validation of those nanosystems to smooth the process of clinical translation.
金黄色葡萄球菌（S. aureus）被世界卫生组织视为需要新疗法的高优先级病原体。对于与生物膜植入物相关的感染，这一点尤为重要，因为唯一可用的治疗选择是手术联合抗生素治疗。因此，这些感染给医疗保健系统带来了经济负担。一种新的策略已经出现来解决这个问题：对于小虫子，小颗粒。在这里，我们描述了如何研究基于纳米技术的系统来治疗 S. aureus 生物膜。强调了它们的特点、缺点以及对这些感染治疗产生影响的潜力。此外，我们还概述了用于临床前验证这些纳米系统的生物膜模型和检测方法，以简化临床转化的过程。
